ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 57 filers reported holding ALPINE IMMUNE SCIENCES INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,682,231 | +202.4% | 234,256 | +171.5% | 0.00% | – |
| Q2 2023 | $886,958 | +70.8% | 86,280 | +28.3% | 0.00% | – |
| Q1 2023 | $519,294 | +9.5% | 67,266 | +4.3% | 0.00% | – |
| Q4 2022 | $474,046 | +65.2% | 64,496 | +62.0% | 0.00% | – |
| Q3 2022 | $287,000 | -15.3% | 39,823 | 0.0% | 0.00% | – |
| Q2 2022 | $339,000 | +16.5% | 39,823 | +22.8% | 0.00% | – |
| Q1 2022 | $291,000 | -30.4% | 32,417 | +7.6% | 0.00% | – |
| Q4 2021 | $418,000 | +58.9% | 30,123 | +22.3% | 0.00% | – |
| Q3 2021 | $263,000 | +1.5% | 24,623 | -14.4% | 0.00% | – |
| Q2 2021 | $259,000 | – | 28,760 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $76,809,898 | 25.63% |
| Lynx1 Capital Management LP | 2,404,614 | $27,532,830 | 18.21% |
| GREAT POINT PARTNERS LLC | 3,078,633 | $35,250,348 | 6.42% |
| Ghost Tree Capital, LLC | 664,132 | $7,604,311 | 2.50% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $34,186,918 | 2.27% |
| Paradigm Biocapital Advisors LP | 2,421,743 | $27,728,957 | 1.88% |
| COMMODORE CAPITAL LP | 1,325,000 | $15,171,250 | 1.77% |
| Nan Fung Group Holdings Ltd | 182,280 | $2,087,106 | 1.69% |
| Omega Fund Management, LLC | 153,700 | $1,759,865 | 1.62% |
| Octagon Capital Advisors LP | 750,000 | $8,587,500 | 1.32% |